Comparison of a two- or three-week regimen and a review of treatment of erythema migrans with phenoxymethylpenicillin

Dermatology

Volumn 212, Issue 2, 2006, Pages 160-167

  Aberer, E ^a   Kahofer, P ^a   Binder, B ^a   Kinaciyan, T ^b   Schauperl, H ^a   Berghold, A ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b Universitatsklinik fur Dermatologie   (Austria)

Author keywords

Borrelia burgdorferi; Erythema migrans; Lyme borreliosis; Penicillin

Indexed keywords

DOXYCYCLINE; PENICILLIN V;

ADULT; AGED; ARTHRALGIA; ARTICLE; CLINICAL EXAMINATION; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; ERYTHEMA CHRONICUM MIGRANS; ERYTHEMA NODOSUM; FATIGUE; FEMALE; FOLLOW UP; HUMAN; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PALLIATIVE THERAPY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PRURITUS; RETREATMENT; SEROLOGY; STATISTICAL ANALYSIS; TREATMENT FAILURE; TREATMENT RESPONSE; URTICARIA;

ADULT; AGED; ANTI-BACTERIAL AGENTS; ANTIBODIES, ANTI-IDIOTYPIC; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; ENZYME-LINKED IMMUNOSORBENT ASSAY; ERYTHEMA; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MALE; MIDDLE AGED; PENICILLIN V; PROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 32944476544     PISSN: 10188665     EISSN: None     Source Type: Journal    
DOI: 10.1159/000090657     Document Type: Article

References (41)

1. Steere A: Lyme disease. N Engl J Med 2001; 345:115-125.
2. Wormser GP, Nadelman RB, Dattwyler RJ, Dennis DT, Shapiro ED, Steere AC, Rush TJ, Rahn DW, Coyle PK, Persing DH, Fish D, Luft BJ: Practice guidelines for the treatment of Lyme disease. The Infectious Diseases Society of America. Clin Infect Dis 2000;31(suppl 1):1-14.
3. Loewen PS, Marra CA, Marra F: Systematic review of the treatment of early Lyme disease. Drugs 1999;57:157-173.
4. Weber K: Treatment failure in erythema migrans - a review. Infection 1996;24:73-75.
5. Baradaran-Dilmaghani R, Stanek G: In vitro susceptibility of thirty Borrelia strains from various sources against eight antimicrobial chemotherapeutics. Infection 1996;24:60-63.
6. Seinost G, Dykhuizen DE, Dattwyler RJ, Golde WT, Dunn JJ, Wang IN, Wormser GP, Schriefer ME, Luft BJ: Four clones of Borrelia burgdorferi sensu stricto cause invasive infection in humans. Infect Immun 1999;67:3518-3524.
7. Strle F: Principles of the diagnosis and antibiotic treatment of Lyme borreliosis. Wien Klin Wochenschr 1999;111:911-915.
8. Asbrink E, Olsson I, Hovmark A: Erythema chronicum migrans Afzelius in Sweden. A study on 231 patients. Zbl Bakt Hyg A 1986; 263:229-236.
9. Weber K, Preac-Mursic V, Wilske B, Thurmayr R, Neubert U, Scherwitz C: A randomized trial of ceftriaxone versus oral penicillin for the treatment of early Lyme borreliosis. Infection 1990;18:91-96.
10. Weber K, Wilske B, Preac-Mursic V, Thurmayr R: Azithromycin versus penicillin V for the treatment of early Lyme borreliosis. Infection 1993;21:367-372.
11. Bennet L, Danell S, Berglund J: Clinical outcome of erythema migrans after tretament with phenoxymethylpenicillin. Scand J Infect Dis 2003;35:129-147.
12. Steere AC, Malawista SE, Newman JH, Spieler PN, Bartenhagen NH: Antibiotic therapy in Lyme disease. Ann Intern Med 1980;93:1-8.
13. Treatment of Lyme disease. Med Lett Drugs Ther 1992;34:95-97.
14. Treatment of Lyme disease. Med Lett Drugs Ther 1997;39:47-48.
15. Treatment of Lyme disease. Med Lett Drugs Ther 2000;42:37-39.
16. Nadelmann RB, Wormser GP: Lyme borreliosis. Lancet 1998;352:557-565.
17. Strle F, Ruzic E, Cimpermann J: Erythema migrans: comparison of treatment with azithromycin, doxycycline and phenoxymethylpenicillin. J Antimicrob Chemother 1992;30: 543-550.
18. Hansen K, Hovmark A, Lebech AM, Lebech K, Olsson I, Halkier-Sorensen L, Olsson E, Asbrink E: Roxithromycin in Lyme borreliosis: discrepant results of an in vitro and in vivo animal susceptibility study and a clinical trial in patients with erythema migrans. Acta Derm Venereol 1992;72:297-300.
19. Klade H, Aberer E: Late complaints after erythema migrans. J Spirochetal Tick-Borne Dis 1994;1:52-56.
20. Breier F, Kunz G, Klade H, Stanek G, Aberer E: Erythema migrans: three weeks treatment for prevention of late Lyme borreliosis. Infection 1996;24:69-74.
21. Krbkova L, Stanek G: Therapy of Lyme borreliosis in children. Infection 1996;24:170-173.
22. Arnez M, Radsel-Medvescek A, Pleterski-Rigler D, Ruzic-Sabljic E, Strle F: Comparison of cefuroxime axetil and phenoxymethylpenicillin for the treatment of children with solitary erythema migrans. Wien Klin Wochenschr 1999;111:916-922.
23. Maraspin V, Cimperman J, Lotric-Furlan S, Pleterski-Rigler D, Strle F: Erythema migrans in pregnancy. Wien Klin Wochenschr 1999; 111:933-940.
24. Lomholt H, Lebech AM, Hansen K, Brandrup F, Halkier-Sorensen L: Long-term serological follow-up of patients treated for chronic cutaneous borreliosis or culture-positive erythema migrans. Acta Derm Venereol 2000;80:362-366.
25. Arnez M, Pleterski-Rigler D, Luznik-Bufon T, Ruzic-Sabljic E, Strle F: Solitary erythema migrans in children: comparison of treatment with azithromycin and phenoxymethylpenicillin. Wien Klin Wochenschr 2002;114:498-504.
26. Steere AC, Hutchinson GJ, Rahn DW, Sigal LH, Craft JE, De Sanna ET, Malawista SE: Treatment of the early manifestations of Lyme disease. Ann Intern Med 1983;99:22-26.
27. Wilske B, Fingerle V: Therapie der Lyme Borreliose. MMW Fortschr Med 2000;142:32-33.
28. European Concerted Action against Lyme borreliosis (EUCALB): http://www.dis.strath.ac. uk/vie/Lyme EU/.
29. Stanek G: Durch Zecken übertragene Krankheitserreger. Antibiot Monitor 2002;5:65-88.
30. Wormser GP, Ramanathan R, Nowakowski J, McKenna D, Holmgren D, Visintainer P, Dornbush R, Singh B, Nadelman RB: Duration of antibiotic therapy for early Lyme disease: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2003;138: 697-704.
31. Klempner MS, Hu LT, Evans J, Schmid CH, Johnson GM, Trevino RP, Norton D, Levy L, Wall D, Mc Call J, Kosinski M, Weinstein A: Two controlled trials of antibiotic treatment in patients with persistent symptoms and a history of Lyme disease. N Engl J Med 2001;345: 85-92.
32. Jacobsson L, Lindgarde F, Manthorpe R: The commonest rheumatic complaints of over six weeks' duration in a twelve-month period in a defined Swedish population. Prevalences and relationships. Scand J Rheumatol 1989;18: 353-360.
33. Dattwyler RJ, Volkman DJ, Conaty SM, Platkin SP, Luft BJ: Amoxycillin plus probenecid versus doxycycline for treatment of erythema migrans borreliosis. Lancet 1990;336:1404-1406.
34. Nadelmann R, Luger SW, Frank E, Wisniewski M, Collins JJ, Wormser GP: Comparison of cefuroxime axetil and doxycycline in the treatment of early Lyme disease. Ann Intern Med 1992;117:273-280.
35. Weissenbacher S, Ring J, Hofmann H: Gabapentin for the symptomatic treatment of chronic neuropathic pain in patients with late-stage Lyme borreliosis: a pilot study. Dermatology 2005;211:123-127.
36. Luft BJ, Dattwyler RJ, Johnson RC, Luger SW, Bosler EM, Rahn DW, Masters EJ, Grunwaldt E, Gadgil SD: Azithromycin compared with amoxicillin in the treatment of erythema migrans. A double-blind, randomized, controlled trial. Ann Intern Med 1996;124:785-791.
37. Luger SW, Paparone P, Wormser GP, Nadelmann RB, Grunwaldt E, Gomez G, Wisniewski M, Collins JJ: Comparison of cefuroxime axetil and doxycycline in treatment of patients with early Lyme disease associated with erythema migrans. Antimicrob Agents Chemother 1995;39:661-667.
38. Feder HM, Gerber MA: Persistence of serum antibodies to Borrelia burgdorferi in patients treated for Lyme disease. Clin Infect Dis 1992; 15:788-793.
39. Hammers-Berggren S, Lebech AM, Karlsson M, Svenungsson B, Hansen K, Stiernstedt G: Serological follow-up after treatment of patients with erythema migrans and neuroborreliosis. J Clin Microbiol 1994;32:1519-1525.
40. Aberer E, Kehldorfer M, Binder B, Schauperl H: The outcome of Lyme borreliosis in children. Wien Klin Wochenschr 1999;22-23: 941-944.
41. Wilske B, Fingerle V, Herzer P, Hofmann A, Lehnert G, Peters H, Poster HW, Preac-Mursic V, Soutschek E, Weber K: Recombinant immunoblot in the serodiagnosis of Lyme borreliosis. Med Microbiol Immunol 1993;182: 255-270.